Drug Approval | March 23, 2024
Zydus receives tentative approval from USFDA for Letermovir Tablets
Letermovir tablets, 240 mg and 480 mg had annual sales of USD 289.5 mn in the United States (IQVIA MAT Jan-24)
Letermovir tablets, 240 mg and 480 mg had annual sales of USD 289.5 mn in the United States (IQVIA MAT Jan-24)
The approved product has an estimated market size of US$ 44.5 million for the twelve months ending January 2024
Chlorpromazine Hydrochloride Injection is used to treat certain mental/mood disorders
The product will be launched in March 2024
Minzoya Tablets are indicated for use by females of reproductive potential to prevent pregnancy
Isosorbide mononitrate is used to prevent chest pain (angina) in patients with a certain heart condition (coronary artery disease)
It is indicated for the inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation
Bromfenac Ophthalmic Solution 0.075% (RLD BromSite) had estimated annual sales of USD 15 million in the U.S.
Dexamethasone is used to treat conditions such as arthritis, blood/hormone disorders, allergic reactions
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
Subscribe To Our Newsletter & Stay Updated
